ImmunityBio (IBRX) EBT (2014 - 2026)

ImmunityBio (IBRX) has reported EBT for 13 consecutive years, with -$632.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 387.13% year-over-year to -$632.8 million; the TTM figure through Mar 2026 stood at -$854.5 million (down 108.71% YoY), while the FY2025 annual figure was -$351.6 million, up 15.0% from the prior year.
• EBT declined to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.1 million in the prior quarter.
• Across five years, EBT topped out at -$59.2 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
• Historically, EBT has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Annual changes were most pronounced in 2024 — EBT surged 74.65% — and 2026, when it sank 387.13%.
• ImmunityBio's EBT stood at -$108.3 million in 2022, then sank by 115.58% to -$233.5 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then declined by 4.92% to -$62.1 million in 2025, then sank by 919.1% to -$632.8 million in 2026.
• Business Quant data shows IBRX's EBT at -$632.8 million in Q1 2026, -$62.1 million in Q4 2025, and -$67.3 million in Q3 2025.